Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1737209 | 0.93 | ENPP2 (0.38) | FABP3FABP4ENPP2NPC1RAB9A | |
| SCHEMBL1736324 | 0.92 | PLA2G2A (0.38) | FABP3FABP4ENPP2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL1736928 | 0.92 | ENPP2 (0.37) | FABP3FABP4ENPP2NPC1RAB9A | |
| SCHEMBL1735831 | 0.92 | FABP4 (0.45) | FABP4MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL1735926 | 0.91 | USP2 (0.41) | FABP4NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1735607 | 0.91 | PRMT5 (0.42) | FABP4MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL1737224 | 0.90 | TP53 (0.44) | FABP4MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL1737529 | 0.90 | TP53 (0.38) | FABP3FABP4ENPP2NPC1RAB9A | |
| SCHEMBL1739451 | 0.90 | L3MBTL1 (0.38) | ENPP2NPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1738183 | 0.89 | L3MBTL1 (0.38) | ENPP2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784404-B1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2011-11-16 | — | — | EP | claimed |
| US-20110263306-A1 | COMPUTER SYSTEM AND PROGRAM | NAMCO BANDAI GAMES INC. (JP) | 2011-10-27 | — | — | US | claimed |
| US-7662832-B2 | Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2010-02-16 | — | — | US | claimed |
| US-20070219230-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2007-09-20 | — | — | US | claimed |
| US-8188114-B2 | Pyrrolo[2,3-C]pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2012-05-29 | — | — | US | disclosed |
| EP-1784404-B1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263306-A1 | COMPUTER SYSTEM AND PROGRAM | NAMCO BANDAI GAMES INC. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20100069430-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-7662832-B2 | Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2010-02-16 | — | — | US | disclosed |
| US-20070219230-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069430-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | PGA5, ATP6AP1, ATP6V1H | FABP3 4315/4885FABP4 4680/4885ENPP2 3571/4885 |
| US-20070219230-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | PGA5, ATP6AP1, ATP6V1H | FABP3 4315/4885FABP4 4680/4885ENPP2 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.